TipRanks
Advertisement
Advertisement
Oragenics begins Phase IIa dosing of concussion drug ONP-002 in Australia
PremiumCompany AnnouncementsOragenics begins Phase IIa dosing of concussion drug ONP-002 in Australia
6M ago
Oragenics Sets New 2025 Annual Shareholder Meeting Date
Premium
Company Announcements
Oragenics Sets New 2025 Annual Shareholder Meeting Date
7M ago
Oragenics receives audit opinion with going concern explanation
Premium
The Fly
Oragenics receives audit opinion with going concern explanation
7M ago
Oragenics receives HREC approval for Phase IIa trial of ONP-002 in Australia
PremiumThe FlyOragenics receives HREC approval for Phase IIa trial of ONP-002 in Australia
8M ago
Oragenics previews targeted milestones for 2026
Premium
The Fly
Oragenics previews targeted milestones for 2026
8M ago
Oragenics partners with Duck Flats Pharma to support FDA IND trial design
Premium
The Fly
Oragenics partners with Duck Flats Pharma to support FDA IND trial design
9M ago
Oragenics regains compliance with NYSE
PremiumThe FlyOragenics regains compliance with NYSE
1y ago
Oragenics, Receptor.AI partner to accelerate pipeline development
Premium
The Fly
Oragenics, Receptor.AI partner to accelerate pipeline development
1y ago
Oragenics Appoints Natasha Giordano to Board of Directors
Premium
Company Announcements
Oragenics Appoints Natasha Giordano to Board of Directors
1y ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―